お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
961734

肺動脈性肺高血圧症 (PAH) :2029年までの疫学予測

Pulmonary Arterial Hypertension - Epidemiology Forecast to 2029

出版日: | 発行: GlobalData | ページ情報: 英文 | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
肺動脈性肺高血圧症 (PAH) :2029年までの疫学予測
出版日: 2020年09月15日
発行: GlobalData
ページ情報: 英文
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本) における肺動脈性肺高血圧症 (PAH) と診断された有病者数は、2019年の12,487人から、2029年の12,752人まで増加し、AGRで0.21%の成長が予測されています。

当レポートでは、主要7ヶ国における肺動脈性肺高血圧症 (PAH) について調査分析し、危険因子と世界の動向、10年間の疫学予測について、体系的な情報を提供しています。

目次

第1章 目次

第2章 肺動脈性肺高血圧症 (PAH) :エグゼクティブサマリー

第3章 疫学

  • 病気の背景
  • 危険因子と併存疾患
  • 世界動向と歴史的動向
  • 予測手法
    • 情報源
    • 予測の前提条件と手法
  • PAHの疫学予測
    • PAHと診断された発症者数
    • PAHと診断された発症者数:性別
    • PAHと診断された発症者数:年齢別
    • PAHと診断された有病者数
    • PAHと診断された有病者数:性別
    • PAHと診断された有病者数:年齢別
    • PAHと診断された有病者数:NYHA機能分類別
    • PAHと診断された有病者数:併存疾患別
  • 議論
    • 疫学予測の考察
    • COVID-19の影響
    • 分析の限界
    • 分析の強み

第4章 付録

図表

List of Tables

List of Tables

  • Table 1: Summary of Updated Data Types
  • Table 2: Risk Factors and Comorbidities for PAH
  • Table 3: Diagnosed Prevalent Cases of PAH by Comorbidities, N, Both Sexes, All Ages, 2019

List of Figures

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, 2019 and 2029
  • Figure 2: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, 2019 and 2029
  • Figure 3: 7MM, Diagnosed Incidence of PAH (Cases per 100,000 Population), Both Sexes, All Ages, 2019
  • Figure 4: 7MM, Diagnosed Prevalence of PAH (%), Both Sexes, All Ages, 2019
  • Figure 5: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of PAH
  • Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PAH by NYHA Functional Classes
  • Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PAH by Comorbidities: CTD, PH, CHD, and COPD
  • Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PAH by Comorbidities: Scleroderma, Diabetes
  • Figure 9: 7MM, Diagnosed Incident Cases of PAH, N, Both Sexes, All Ages, 2019
  • Figure 10: 7MM, Diagnosed Incident Cases of PAH, N, by Sex, All Ages, 2019
  • Figure 11: 7MM, Diagnosed Incident Cases of PAH by Age, N, Both Sexes, 2019
  • Figure 12: 7MM, Diagnosed Prevalent Cases of PAH, N, Both Sexes, All Ages, 2019
  • Figure 13: 7MM, Diagnosed Prevalent Cases of PAH, N, by Sex, All Ages, 2019
  • Figure 14: 7MM, Diagnosed Prevalent Cases of PAH by Age, N, Both Sexes, 2019
  • Figure 15: 7MM, Diagnosed Prevalent Cases of PAH by NYHA Functional Classes, N, Both Sexes, All Ages, 2019
目次
Product Code: GDHCER250-20

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vascular proliferation and remodeling of the small pulmonary arteries (Humbert et al., 2004; Humbert et al., 2010; Simonneau et al., 2004). In PAH, blood vessels in the lungs are narrowed, blocked, or destroyed. The damage slows blood flow through the lungs (Mayo Clinic, 2020). This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure (Humbert et al., 2004, 2010; Simonneau et al., 2004).

GlobalData epidemiologists utilized national databases, registries, and robust peer-reviewed journal articles to build the diagnosed incident and diagnosed prevalent cases of PAH forecast in the 7MM. GlobalData epidemiologists used registry data for the forecast of diagnosed incident cases and diagnosed prevalent cases of PAH in the US and 5EU, and then adjusted them for underestimation. For the diagnosed incident and diagnosed prevalent cases of PAH forecast for Japan, GlobalData epidemiologists used data available from the Ministry of Health statistics in Japan that reflect the accurate patient population. GlobalData epidemiologists kept the forecast methodology consistent across the 7MM. The report and model include a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of PAH in the 7MM, segmented by age, sex, NYHA functional classes, and comorbidities.

The following data describes epidemiology of PAH. In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of PAH from 12,487 cases in 2019 to 12,752 cases in 2029, at an AGR of 0.21% over the forecast period. The diagnosed prevalent cases of PAH in the 7MM will increase from 67,369 cases in 2019 to 68,241 cases in 2029, at an AGR of 0.13%. PAH occurs twice as frequently in women as in men. These trends are reflected in GlobalData's forecast for the diagnosed incident and diagnosed prevalent cases for the 7MM.

Scope

  • The Pulmonary Arterial Hypertension (PAH) Epidemiology Report provides an overview of the risk factors and global trends of PAH in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of PAH segmented by sex and age (all ages). The prevalent cases of PAH are also segmented by New York Heart Association (NYHA) functional classes (NYHA functional classes I and II, NYHA functional class III, and NYHA functional class IV), and comorbidities (connective tissue disease, scleroderma, diabetes, chronic obstructive pulmonary disease, portal hypertension, and coronary heart disease) in these markets.
  • The PAH epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Pulmonary Arterial Hypertension Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global PAH market.
  • Quantify patient populations in the global PAH market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PAH therapeutics in each of the markets covered.
  • Understand magnitude of PAH population by severity at diagnosis.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Pulmonary Arterial Hypertension: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for PAH (2019-2029)
    • 3.5.1 Diagnosed Incident Cases of PAH
    • 3.5.2 Sex-Specific Diagnosed Incident Cases of PAH
    • 3.5.3 Age-Specific Diagnosed Incident Cases of PAH
    • 3.5.4 Diagnosed Prevalent Cases of PAH
    • 3.5.5 Sex-Specific Diagnosed Prevalent Cases of PAH
    • 3.5.6 Age-Specific Diagnosed Prevalent Cases of PAH
    • 3.5.7 Diagnosed Prevalent Cases of PAH by NYHA Functional Classes
    • 3.5.8 Diagnosed Prevalent Cases of PAH by Comorbidities
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Coronavirus Disease 2019 (COVID-19) Impact
    • 3.6.3 Limitations of the Analysis
    • 3.6.4 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.